|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Sun K, Zheng R, Zeng H, Zhang S,
Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality
in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun KX, Zheng RS, Zeng HM, Zhang SW, Zou
XN, Gu XY, Xia CF, Yang ZX, Li H, Chen WQ and He J: The incidence
and mortality of lung cancer in China, 2014. Zhonghua Zhong Liu Za
Zhi. 40:805–811. 2018.(In Chinese). PubMed/NCBI
|
|
5
|
Gamerith G, Kocher F, Rudzki J and Pircher
A: ASCO 2018 NSCLC highlights-combination therapy is key. Memo.
11:266–271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong J, Li B, Lin D, Zhou Q and Huang D:
Advances in targeted therapy and immunotherapy for non-small cell
lung cancer based on accurate molecular typing. Front Pharmacol.
10:2302019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelly AD and Issa JJ: The promise of
epigenetic therapy: Reprogramming the cancer epigenome. Curr Opin
Genet Dev. 42:68–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schiffmann I, Greve G, Jung M and Lübbert
M: Epigenetic therapy approaches in non-small cell lung cancer:
Update and perspectives. Epigenetics. 11:858–870. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mehta A, Dobersch S, Romero-Olmedo AJ and
Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer
Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
French CA: Small-molecule targeting of BET
proteins in cancer. Adv Cancer Res. 131:21–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pervaiz M, Mishra P and Günther S:
Bromodomain drug discovery-the past, the present, and the future.
Chem Rec. 18:1808–1817. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Doroshow DB, Eder JP and LoRusso PM: BET
inhibitors: A novel epigenetic approach. Ann Oncol. 28:1776–1787.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu
JJ and Ding JY: High level of BRD4 promotes non-small cell lung
cancer progression. Oncotarget. 7:9491–9500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P,
Cheng Z and Wang X: Targeting BRD4 proteins suppresses the growth
of NSCLC through downregulation of eIF4E expression. Cancer Biol
Ther. 19:407–415. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hines J, Lartigue S, Dong H, Qian Y and
Crews CM: MDM2-recruiting PROTAC offers superior, synergistic
antiproliferative activity via simultaneous degradation of BRD4 and
stabilization of p53. Cancer Res. 79:251–262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y and Vakoc CR: Targeting cancer cells
with BET bromodomain inhibitors. Cold Spring Harb Perspect Med.
7:a0266742017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lam LT, Lin X, Faivre EJ, Yang Z, Huang X,
Wilcox DM, Bellin RJ, Jin S, Tahir SK, Mitten M, et al:
Vulnerability of small-cell lung cancer to apoptosis induced by the
combination of BET bromodomain proteins and BCL2 inhibitors. Mol
Cancer Ther. 16:1511–1520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu C, Buczkowski KA, Zhang Y, Asahina H,
Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK and Hammerman PS:
NSCLC driven by DDR2 mutation is sensitive to dasatinib and JQ1
combination therapy. Mol Cancer Ther. 14:2382–2389. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiong Y, Huang BY and Yin JY:
Pharmacogenomics of platinum-based chemotherapy in non-small cell
lung cancer: Focusing on DNA repair systems. Med Oncol. 34:482017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang C, Wang H, Zhang B, Chen Y, Zhang Y,
Sun X, Xiao G, Nan K, Ren H and Qin S: LCL161 increases
paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
J Exp Clin Cancer Res. 35:1582016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu J, Su C, Zhao F, Tao J, Hu D, Shi A,
Pan J and Zhang Y: Paclitaxel promotes lung cancer cell apoptosis
via MEG3-P53 pathway activation. Biochem Biophys Res Commun.
504:123–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ruiz-Ceja KA and Chirino YI: Current
FDA-approved treatments for non-small cell lung cancer and
potential biomarkers for its detection. Biomed Pharmacother.
90:24–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan H, Hu J and Liu S: Efficacy and safety
of nanoparticle albumin-bound paclitaxel in non-small cell lung
cancer: A systematic review and meta-analysis. Artif Cells Nanomed
Biotechnol. 47:268–277. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma Z, Zhu L, Luo X, Zhai S, Li P and Wang
X: Perifosine enhances mTORC1-targeted cancer therapy by activation
of GSK3β in NSCLC cells. Cancer Biol Ther. 13:1009–1017. 2014.
View Article : Google Scholar
|
|
29
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu S, Yang L, Wu D, Gao Z, Li P, Huang W
and Wang X: AEG-1 induces gastric cancer metastasis by upregulation
of eIF4E expression. J Cell Mol Med. 21:3481–3493. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang W, Yang L, Liang S, Liu D, Chen X,
Ma Z, Zhai S, Li P and Wang X: AEG-1 is a target of perifosine and
is over-expressed in gastric dysplasia and cancers. Dig Dis Sci.
58:2873–2880. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Filippakopoulos P, Qi J, Picaud S, Shen Y,
Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et
al: Selective inhibition of BET bromodomains. Nature.
468:1067–1073. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce
LA, Thompson RC, Muller S, Knapp S and Wang J: Inhibition of BET
bromodomain targets genetically diverse glioblastoma. Clin Cancer
Res. 19:1748–1759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jang JE, Eom JI, Jeung HK, Cheong JW, Lee
JY, Kim JS and Min YH: AMPK-ULK1-mediated autophagy confers
resistance to BET inhibitor JQ1 in acute myeloid leukemia stem
cells. Clin Cancer Res. 23:2781–2794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin JF, Lin YC, Tsai TF, Chen HE, Chou KY
and Hwang TI: Cisplatin induces protective autophagy through
activation of BECN1 in human bladder cancer cells. Drug Des Devel
Ther. 11:1517–1533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu
LZ and Jiang BH: Downregulation of ATG14 by EGR1-MIR152 sensitizes
ovarian cancer cells to cisplatin-induced apoptosis by inhibiting
cyto-protective autophagy. Autophagy. 11:373–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma Y, Cheng Z, Liu J, Torre-Healy L,
Lathia JD, Nakano I, Guo Y, Thompson RC, Freeman ML and Wang J:
Inhibition of farnesyltransferase potentiates NOTCH-targeted
therapy against glioblastoma stem cells. Stem Cell Reports.
9:1948–1960. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Welti J, Sharp A, Yuan W, Dolling D, Nava
Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, et al:
Targeting bromodomain and extra-terminal (BET) family proteins in
castration-resistant prostate cancer (CRPC). Clin Cancer Res.
24:3149–3162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shu S, Lin CY, He HH, Witwicki RM,
Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, et
al: Response and resistance to BET bromodomain inhibitors in
triple-negative breast cancer. Nature. 529:413–417. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Momeny M, Eyvani H, Barghi F, Ghaffari SH,
Javadikooshesh S, Hassanvand Jamadi R, Esmaeili F, Alishahi Z,
Zaghal A, Bashash D, et al: Inhibition of bromodomain and
extraterminal domain reduces growth and invasive characteristics of
chemoresistant ovarian carcinoma cells. Anticancer Drugs.
29:1011–1020. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Klingbeil O, Lesche R, Gelato KA, Haendler
B and Lejeune P: Inhibition of BET bromodomain-dependent XIAP and
FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic
agents. Cell Death Dis. 7:e23652016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zengerle M, Chan KH and Ciulli A:
Selective small molecule induced degradation of the BET bromodomain
protein BRD4. ACS Chem Biol. 10:1770–1777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z,
Guo F, He Y, Liu Y, Huang Q, et al: An integrated bioinformatics
platform for investigating the human E3 ubiquitin ligase-substrate
interaction network. Nat Commun. 8:3472017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gadd MS, Testa A, Lucas X, Chan KH, Chen
W, Lamont DJ, Zengerle M and Ciulli A: Structural basis of PROTAC
cooperative recognition for selective protein degradation. Nat Chem
Biol. 13:514–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun B, Fiskus W, Qian Y, Rajapakshe K,
Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, et al: BET
protein proteolysis targeting chimera (PROTAC) exerts potent lethal
activity against mantle cell lymphoma cells. Leukemia. 32:343–352.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
To KKW, Tong WS and Fu LW: Reversal of
platinum drug resistance by the histone deacetylase inhibitor
belinostat. Lung Cancer. 103:58–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Iniguez AB, Alexe G, Wang EJ, Roti G,
Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, et al:
Resistance to epigenetic-targeted therapy engenders tumor cell
vulnerabilities associated with enhancer remodeling. Cancer Cell.
34:922–938.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hishiki K, Akiyama M, Kanegae Y, Ozaki K,
Ohta M, Tsuchitani E, Kaito K and Yamada H: NF-κB signaling
activation via increases in BRD2 and BRD4 confers resistance to the
bromodomain inhibitor I-BET151 in U937 cells. Leuk Res. 74:57–63.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zong D, Gu J, Cavalcante GC, Yao W, Zhang
G, Wang S, Owonikoko TK, He X and Sun SY: BRD4 levels determine the
response of human lung cancer cells to BET degraders that potently
induce apoptosis through suppression of Mcl-1. Cancer Res.
80:2380–2393. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Adeegbe DO, Liu S, Hattersley MM, Bowden
M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, et
al: BET bromodomain inhibition cooperates with PD-1 blockade to
facilitate antitumor response in Kras-mutant non-small cell lung
cancer. Cancer Immunol Res. 6:1234–1245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li L, Wang Y, Jiao L, Lin C, Lu C, Zhang
K, Hu C, Ye J, Zhang D, Wu H, et al: Protective autophagy decreases
osimertinib cytotoxicity through regulation of stem cell-like
properties in lung cancer. Cancer Lett. 452:191–202. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Henssen A, Thor T, Odersky A, Heukamp L,
El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm
A, et al: BET bromodomain protein inhibition is a therapeutic
option for medulloblastoma. Oncotarget. 4:2080–2095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zuber J, Shi J, Wang E, Rappaport AR,
Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al:
RNAi screen identifies Brd4 as a therapeutic target in acute
myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou S, Zhang S, Wang L, Huang S, Yuan Y,
Yang J, Wang H, Li X, Wang P, Zhou L, et al: BET protein inhibitor
JQ1 downregulates chromatin accessibility and suppresses metastasis
of gastric cancer via inactivating RUNX2/NID1 signaling.
Oncogenesis. 9:332020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kanojia D, Panek WK, Cordero A, Fares J,
Xiao A, Savchuk S, Kumar K, Xiao T, Pituch KC, Miska J, et al: BET
inhibition increases βIII-tubulin expression and sensitizes
metastatic breast cancer in the brain to vinorelbine. Sci Transl
Med. 12:eaax28792020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hemming ML, Lawlor MA, Andersen JL, Hagan
T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA,
Demetri GD and Bradner JE: Enhancer domains in gastrointestinal
stromal tumor regulate KIT expression and are targetable by BET
bromodomain inhibition. Cancer Res. 79:994–1009. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Abruzzese MP, Bilotta MT, Fionda C,
Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R,
Paolini R, Santoni A and Cippitelli M: The homeobox transcription
factor MEIS2 is a regulator of cancer cell survival and IMiDs
activity in multiple myeloma: Modulation by bromodomain and
extra-terminal (BET) protein inhibitors. Cell Death Dis.
10:3242019. View Article : Google Scholar : PubMed/NCBI
|
